CD19-targeted antibody-drug conjugate 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 
28 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma
2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-5)

Ongoing
3
350
Europe, RoW
Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin, ADCT-402, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for infusion, TRUXIMA, Bendacitabin 38 mg/ml, Oxali-Bendalis 5 mg/ml
ADC Therapeutics SA, ADC THERAPEUTICS SA, ADC Therapeutics SA
Diffuse Large B-Cell Lymphoma (DLBCL), Lymphoma, Diseases [C] - Cancer [C04]
 
 
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Checkmark Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Hourglass Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
Hourglass Sep 2021 - Dec 2021 : Submission for r/r DLBCL
Active, not recruiting
3
440
Europe, Canada, Japan, US, RoW
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin
ADC Therapeutics S.A., ADC Therapeutics SA
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
06/25
06/28
Glo-BNHL, NCT05991388: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

Recruiting
2/3
210
Europe
Odronextamab, REGN-1979, Loncastuximab tesirine, ADCT-402, Rituximab, Ifosfamide, Carboplatin, Etoposide, Etoposide Phosphate, Dexamethasone, CAR T-cells (TBC)
University of Birmingham, Cancer Research UK, Fight Kids Cancer, Regeneron Pharmaceuticals, ADC Therapeutics S.A.
B-cell Non Hodgkin Lymphoma
05/31
05/33
2021-000715-23: Loncastuximab tesirine administered as a consolidation treatment after immunochemotherapy in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) Loncastuximab tesirine somministrato come trattamento di consolidamento dopo immunochemioterapia in pazienti con linfoma a cellule del mantello (MCL) ricaduto/refrattario (R/R)

Not yet recruiting
2
56
Europe
Zynlonta, [IMP1], Powder for concentrate for solution for infusion, Zynlonta
FONDAZIONE ITALIANA LINFOMI ONLUS, ADC Therapeutics SA
Bruton Tyrosine Kinase inhibitors (BTKi) treated (or BTKi intolerant) relapsed/refractory (R/R) Mantle Cell Lymphoma (MCL). Linfoma a cellule del mantello (MCL) recidivati/refrattari (R/R) dopo trattamento con inibitori della tirosina chinasi di Bruton (BTKi) o intolleranti a BTKi., Bruton Tyrosine Kinase inhibitors (BTKi) treated (or BTKi intolerant) relapsed/refractory (R/R) Mantle Cell Lymphoma (MCL). Linfoma a cellule del mantello (MCL) recidivati/refrattari (R/R) dopo trattamento con inibitori della tirosina chinasi di Bruton (BTKi) o intolleranti a BTKi., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2022-001147-24: Use of LOncastuximab Tesirine in patients with RElapsed/Refractory Diffuse Large B-Cell LYmphoma (DLBCL) or High Grade B-Cell Lymphoma (HGBCL) who have progressive disease after CAR T-cell treatment - LORELY Uso di Loncastuximab Tesirina in pazienti con linfoma diffuso a grandi cellule B (DLBCL) o linfoma a cellule B di alto grado (HGBCL) recidivante/refrattario che hanno avuto progressione di malattia dopo il trattamento con CAR-T - LORELY

Not yet recruiting
2
50
Europe
Zynlonta, [ADCT-402], Powder for infusion
IRCCS ISTITUTO CLINICO HUMANITAS
Patients affected by relapsed/refractory DLBCL or HGBCL failing CAR T-cell therapy Pazienti affetti da DLBCL o HGBCL recidivante/refrattario che non hanno superato la terapia con cellule CAR-T, Patients affected by relapsed/refractory DLBCL or HGBCL failing CAR T-cell therapy Pazienti affetti da DLBCL o HGBCL recidivante/refrattario che non hanno superato la terapia con cellule CAR-T, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT04998669: Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Recruiting
2
100
US
Loncastuximab tesirine, ADCT-402, Rituximab, Rituxan
Juan P. Alderuccio, MD, ADC Therapeutics S.A.
Follicular Lymphoma
08/27
08/30
NCT05672251: Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recruiting
2
36
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Loncastuximab Tesirine, ADC ADCT-402, ADCT-402, Anti-CD19 PBD-conjugate ADCT-402, Loncastuximab Tesirine-lpyl, Zynlonta, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
04/25
04/25
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Recruiting
2
49
Europe
Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
Fondazione Italiana Linfomi - ETS
Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
04/26
04/29
NCT06788964: Loncastuximab Tesirine and Rituximab as Bridging Therapy Prior to Standard-of-care CD19 CAR T-cell Therapy in Patients With Large B-cell Lymphoma

Not yet recruiting
2
29
US
Loncastuximab Tesirine, Rituximab
University of Utah, ADC Therapeutics S.A.
Relapsed or Refractory Large B-cell Lymphoma
03/27
03/30
LOTIS-9, NCT05144009: A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)

Terminated
2
41
Europe, US
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab
ADC Therapeutics S.A.
Diffuse Large B-cell Lymphoma
01/24
01/24
NCT05190705: Loncastuximab Tesirine in WM

Recruiting
2
36
US
Loncastuximab Tesirine, Zynlonta, Dexamethasone, Decadron, Dexamethasone Intensol, Dexpak, Taperpak
Shayna Sarosiek, MD, ADC Therapeutics S.A.
Waldenstrom Macroglobulinemia
05/25
08/27
NCT05453396: Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Recruiting
2
40
US
Loncastuximab Tesirine, ADC ADCT-402, ADCT-402, Anti-CD19 PBD-conjugate ADCT-402, Loncastuximab Tesirine-lpyl, Zynlonta, MT 2111, MT-2111, MT2111
University of Washington
Post-Transplant Lymphoproliferative Disorder, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Neoplastic Post-Transplant Lymphoproliferative Disorder, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Neoplastic Post-Transplant Lymphoproliferative Disorder
12/25
07/26
NCT05222438: Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant

Withdrawn
2
36
US
loncastuximab tesirine
Barbara Ann Karmanos Cancer Institute
Relapsed Diffuse Large B-cell Lymphoma
12/25
12/25
NCT05464719: A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

Recruiting
2
30
US
Loncastuximab Tesirine, Lonca
M.D. Anderson Cancer Center
Large B-cell Lymphoma, Lymphoma
01/26
01/26
NCT05600686: Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

Recruiting
2
24
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Loncastuximab Tesirine, ADC ADCT-402, ADCT-402, Anti-CD19 PBD-conjugate ADCT-402, Loncastuximab Tesirine-lpyl, Zynlonta, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Vincristine, Leurocristine, VCR, Vincrystine
Joseph Tuscano, National Cancer Institute (NCI), ADC Therapeutics S.A.
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
02/26
02/28
NCT05296070: Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

Recruiting
2
50
US
Loncastuximab tesirine 150 µg/Kg, Loncastuximab tesirine 75µg/Kg
University of Miami, ADC Therapeutics S.A.
Marginal Zone Lymphoma
06/28
06/29
ChiCTR2300072058: A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Completed
2
64
 
Loncastuximab tesirine intravenous injection
Beijing Cancer Hospital; Overland Pharmaceuticals, ADC Therapeutics S.A., Overland Pharmaceuticals
Diffuse Large B-cell Lymphoma
 
 
IGM-2323-001, NCT04082936 / 2021-002339-44: A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Hourglass Jan 2022 - Dec 2022 : Initial data from trial for DLBCL/follicular lymphoma
Hourglass Jan 2021 - Dec 2021 : Completion of enrollment of P1 trial for NHL
Checkmark Safety and efficacy data from trial for r/r NHL at ASH 2021
Dec 2021 - Dec 2021: Safety and efficacy data from trial for r/r NHL at ASH 2021
Checkmark Interim data from trial for r/r NHL at ASH 2020
More
Terminated
1/2
97
Europe, US, RoW
imvotamab
IGM Biosciences, Inc., ADC Therapeutics S.A.
Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL, Mantle Cell Lymphoma, Marginal Zone Lymphoma
02/24
02/24
NCT05658562: A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

Recruiting
1/2
49
Japan
MT-2111, Loncastuximab tesirine
Mitsubishi Tanabe Pharma Corporation
Diffuse Large B-Cell Lymphoma
12/25
08/28
NCT05053659: Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

Recruiting
1
36
US
Loncastuximab tesirine, ADCT-402, lonca, Venetoclax, ABT-199, GDC-0199
Paolo Caimi, MD
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
06/25
12/25
NCT06607549: Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery (SRS) in Patients With Primary and Secondary Central Nervous System Lymphomas (Lonca-R After SRS in CNSL)

Recruiting
1
12
US
Loncastuximab tesirine and rituximab (Lonca-R)
University of Utah, ADC Therapeutics S.A.
Central Nervous System Lymphoma
11/29
11/30
LOTIS 7, NCT04970901: A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Recruiting
1
200
Europe, US, RoW
Loncastuximab Tesirine, ZYNLONTA, ADCT-402, Polatuzumab Vedotin, Glofitamab, Mosunetuzumab, Obinutuzumab
ADC Therapeutics S.A.
B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
12/25
12/26
NCT05660395: A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

Recruiting
1
56
US, RoW
Loncastuximab Tesirine, Zynlonta, ADCT-402
ADC Therapeutics S.A.
Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
12/26
04/27
NCT05971251: Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

Recruiting
1
24
US
Loncastuximab Tesirine and Acalabrutinib
Mayur Narkhede, ADC Therapeutics S.A.
Chronic Lymphocytic Leukemia
12/26
12/28
LONCA, NCT05270057: Loncastuximab Tesirine in Combination with DA-EPOCH-R in Patients with Previously Untreated Aggressive B-cell Lymphoid Malignancies

Recruiting
1
33
US
Etoposide, Etopophos, Toposar, Vepesid, Doxorubicin, Lipodox, Lipodox 50, Doxil, Adriamycin, Rubex, Cyclophosphamide, Cytoxan, Neosar, Endoxan, Procytox, Revimmune, Rituximab, Rituxan, MabThera, Vincristine, Oncovin, Vincasar, Marqibo, Leurocristine, Prednisone, Deltasone, Orasone, Meticorten, Liquid Pred, Loncastuximab Tesirine 0.075 mg/kg by IV, Zynlonta, ADCT-402, loncastuximab tesirine-lpyl, Loncastuximab tesirine 0.12 mg/kg by IV, Loncastuximab tesirine 0.15 mg/kg by IV
Medical College of Wisconsin
B-cell Lymphoma, Burkitt Lymphoma
05/26
05/26
NCT04705454: Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

No Longer Available
N/A
NA
Loncastuximab Tesirine, Zynlonta
ADC Therapeutics S.A.
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
 
 
IKS03 / Iksuda Therap
NCT05365659: IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas

Recruiting
1
140
Europe, Canada, US, RoW
IKS03
Iksuda Therapeutics Ltd.
B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, B-cell Lymphoma
09/25
09/27
ABBV-319 / AbbVie
NCT05512390: A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Recruiting
1
154
Canada, US, RoW
ABBV-319
AbbVie
Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma
02/27
02/27
NV102 / NanoValent Pharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma
2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-5)

Ongoing
3
350
Europe, RoW
Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin, ADCT-402, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for infusion, TRUXIMA, Bendacitabin 38 mg/ml, Oxali-Bendalis 5 mg/ml
ADC Therapeutics SA, ADC THERAPEUTICS SA, ADC Therapeutics SA
Diffuse Large B-Cell Lymphoma (DLBCL), Lymphoma, Diseases [C] - Cancer [C04]
 
 
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Checkmark Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Hourglass Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
Hourglass Sep 2021 - Dec 2021 : Submission for r/r DLBCL
Active, not recruiting
3
440
Europe, Canada, Japan, US, RoW
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin
ADC Therapeutics S.A., ADC Therapeutics SA
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
06/25
06/28
Glo-BNHL, NCT05991388: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

Recruiting
2/3
210
Europe
Odronextamab, REGN-1979, Loncastuximab tesirine, ADCT-402, Rituximab, Ifosfamide, Carboplatin, Etoposide, Etoposide Phosphate, Dexamethasone, CAR T-cells (TBC)
University of Birmingham, Cancer Research UK, Fight Kids Cancer, Regeneron Pharmaceuticals, ADC Therapeutics S.A.
B-cell Non Hodgkin Lymphoma
05/31
05/33
2021-000715-23: Loncastuximab tesirine administered as a consolidation treatment after immunochemotherapy in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) Loncastuximab tesirine somministrato come trattamento di consolidamento dopo immunochemioterapia in pazienti con linfoma a cellule del mantello (MCL) ricaduto/refrattario (R/R)

Not yet recruiting
2
56
Europe
Zynlonta, [IMP1], Powder for concentrate for solution for infusion, Zynlonta
FONDAZIONE ITALIANA LINFOMI ONLUS, ADC Therapeutics SA
Bruton Tyrosine Kinase inhibitors (BTKi) treated (or BTKi intolerant) relapsed/refractory (R/R) Mantle Cell Lymphoma (MCL). Linfoma a cellule del mantello (MCL) recidivati/refrattari (R/R) dopo trattamento con inibitori della tirosina chinasi di Bruton (BTKi) o intolleranti a BTKi., Bruton Tyrosine Kinase inhibitors (BTKi) treated (or BTKi intolerant) relapsed/refractory (R/R) Mantle Cell Lymphoma (MCL). Linfoma a cellule del mantello (MCL) recidivati/refrattari (R/R) dopo trattamento con inibitori della tirosina chinasi di Bruton (BTKi) o intolleranti a BTKi., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2022-001147-24: Use of LOncastuximab Tesirine in patients with RElapsed/Refractory Diffuse Large B-Cell LYmphoma (DLBCL) or High Grade B-Cell Lymphoma (HGBCL) who have progressive disease after CAR T-cell treatment - LORELY Uso di Loncastuximab Tesirina in pazienti con linfoma diffuso a grandi cellule B (DLBCL) o linfoma a cellule B di alto grado (HGBCL) recidivante/refrattario che hanno avuto progressione di malattia dopo il trattamento con CAR-T - LORELY

Not yet recruiting
2
50
Europe
Zynlonta, [ADCT-402], Powder for infusion
IRCCS ISTITUTO CLINICO HUMANITAS
Patients affected by relapsed/refractory DLBCL or HGBCL failing CAR T-cell therapy Pazienti affetti da DLBCL o HGBCL recidivante/refrattario che non hanno superato la terapia con cellule CAR-T, Patients affected by relapsed/refractory DLBCL or HGBCL failing CAR T-cell therapy Pazienti affetti da DLBCL o HGBCL recidivante/refrattario che non hanno superato la terapia con cellule CAR-T, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT04998669: Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Recruiting
2
100
US
Loncastuximab tesirine, ADCT-402, Rituximab, Rituxan
Juan P. Alderuccio, MD, ADC Therapeutics S.A.
Follicular Lymphoma
08/27
08/30
NCT05672251: Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recruiting
2
36
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Loncastuximab Tesirine, ADC ADCT-402, ADCT-402, Anti-CD19 PBD-conjugate ADCT-402, Loncastuximab Tesirine-lpyl, Zynlonta, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
04/25
04/25
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Recruiting
2
49
Europe
Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
Fondazione Italiana Linfomi - ETS
Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
04/26
04/29
NCT06788964: Loncastuximab Tesirine and Rituximab as Bridging Therapy Prior to Standard-of-care CD19 CAR T-cell Therapy in Patients With Large B-cell Lymphoma

Not yet recruiting
2
29
US
Loncastuximab Tesirine, Rituximab
University of Utah, ADC Therapeutics S.A.
Relapsed or Refractory Large B-cell Lymphoma
03/27
03/30
LOTIS-9, NCT05144009: A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)

Terminated
2
41
Europe, US
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab
ADC Therapeutics S.A.
Diffuse Large B-cell Lymphoma
01/24
01/24
NCT05190705: Loncastuximab Tesirine in WM

Recruiting
2
36
US
Loncastuximab Tesirine, Zynlonta, Dexamethasone, Decadron, Dexamethasone Intensol, Dexpak, Taperpak
Shayna Sarosiek, MD, ADC Therapeutics S.A.
Waldenstrom Macroglobulinemia
05/25
08/27
NCT05453396: Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Recruiting
2
40
US
Loncastuximab Tesirine, ADC ADCT-402, ADCT-402, Anti-CD19 PBD-conjugate ADCT-402, Loncastuximab Tesirine-lpyl, Zynlonta, MT 2111, MT-2111, MT2111
University of Washington
Post-Transplant Lymphoproliferative Disorder, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Neoplastic Post-Transplant Lymphoproliferative Disorder, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Neoplastic Post-Transplant Lymphoproliferative Disorder
12/25
07/26
NCT05222438: Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant

Withdrawn
2
36
US
loncastuximab tesirine
Barbara Ann Karmanos Cancer Institute
Relapsed Diffuse Large B-cell Lymphoma
12/25
12/25
NCT05464719: A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

Recruiting
2
30
US
Loncastuximab Tesirine, Lonca
M.D. Anderson Cancer Center
Large B-cell Lymphoma, Lymphoma
01/26
01/26
NCT05600686: Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

Recruiting
2
24
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Loncastuximab Tesirine, ADC ADCT-402, ADCT-402, Anti-CD19 PBD-conjugate ADCT-402, Loncastuximab Tesirine-lpyl, Zynlonta, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Vincristine, Leurocristine, VCR, Vincrystine
Joseph Tuscano, National Cancer Institute (NCI), ADC Therapeutics S.A.
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
02/26
02/28
NCT05296070: Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

Recruiting
2
50
US
Loncastuximab tesirine 150 µg/Kg, Loncastuximab tesirine 75µg/Kg
University of Miami, ADC Therapeutics S.A.
Marginal Zone Lymphoma
06/28
06/29
ChiCTR2300072058: A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Completed
2
64
 
Loncastuximab tesirine intravenous injection
Beijing Cancer Hospital; Overland Pharmaceuticals, ADC Therapeutics S.A., Overland Pharmaceuticals
Diffuse Large B-cell Lymphoma
 
 
IGM-2323-001, NCT04082936 / 2021-002339-44: A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Hourglass Jan 2022 - Dec 2022 : Initial data from trial for DLBCL/follicular lymphoma
Hourglass Jan 2021 - Dec 2021 : Completion of enrollment of P1 trial for NHL
Checkmark Safety and efficacy data from trial for r/r NHL at ASH 2021
Dec 2021 - Dec 2021: Safety and efficacy data from trial for r/r NHL at ASH 2021
Checkmark Interim data from trial for r/r NHL at ASH 2020
More
Terminated
1/2
97
Europe, US, RoW
imvotamab
IGM Biosciences, Inc., ADC Therapeutics S.A.
Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL, Mantle Cell Lymphoma, Marginal Zone Lymphoma
02/24
02/24
NCT05658562: A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

Recruiting
1/2
49
Japan
MT-2111, Loncastuximab tesirine
Mitsubishi Tanabe Pharma Corporation
Diffuse Large B-Cell Lymphoma
12/25
08/28
NCT05053659: Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

Recruiting
1
36
US
Loncastuximab tesirine, ADCT-402, lonca, Venetoclax, ABT-199, GDC-0199
Paolo Caimi, MD
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
06/25
12/25
NCT06607549: Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery (SRS) in Patients With Primary and Secondary Central Nervous System Lymphomas (Lonca-R After SRS in CNSL)

Recruiting
1
12
US
Loncastuximab tesirine and rituximab (Lonca-R)
University of Utah, ADC Therapeutics S.A.
Central Nervous System Lymphoma
11/29
11/30
LOTIS 7, NCT04970901: A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Recruiting
1
200
Europe, US, RoW
Loncastuximab Tesirine, ZYNLONTA, ADCT-402, Polatuzumab Vedotin, Glofitamab, Mosunetuzumab, Obinutuzumab
ADC Therapeutics S.A.
B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
12/25
12/26
NCT05660395: A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

Recruiting
1
56
US, RoW
Loncastuximab Tesirine, Zynlonta, ADCT-402
ADC Therapeutics S.A.
Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
12/26
04/27
NCT05971251: Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

Recruiting
1
24
US
Loncastuximab Tesirine and Acalabrutinib
Mayur Narkhede, ADC Therapeutics S.A.
Chronic Lymphocytic Leukemia
12/26
12/28
LONCA, NCT05270057: Loncastuximab Tesirine in Combination with DA-EPOCH-R in Patients with Previously Untreated Aggressive B-cell Lymphoid Malignancies

Recruiting
1
33
US
Etoposide, Etopophos, Toposar, Vepesid, Doxorubicin, Lipodox, Lipodox 50, Doxil, Adriamycin, Rubex, Cyclophosphamide, Cytoxan, Neosar, Endoxan, Procytox, Revimmune, Rituximab, Rituxan, MabThera, Vincristine, Oncovin, Vincasar, Marqibo, Leurocristine, Prednisone, Deltasone, Orasone, Meticorten, Liquid Pred, Loncastuximab Tesirine 0.075 mg/kg by IV, Zynlonta, ADCT-402, loncastuximab tesirine-lpyl, Loncastuximab tesirine 0.12 mg/kg by IV, Loncastuximab tesirine 0.15 mg/kg by IV
Medical College of Wisconsin
B-cell Lymphoma, Burkitt Lymphoma
05/26
05/26
NCT04705454: Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

No Longer Available
N/A
NA
Loncastuximab Tesirine, Zynlonta
ADC Therapeutics S.A.
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
 
 
IKS03 / Iksuda Therap
NCT05365659: IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas

Recruiting
1
140
Europe, Canada, US, RoW
IKS03
Iksuda Therapeutics Ltd.
B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, B-cell Lymphoma
09/25
09/27
ABBV-319 / AbbVie
NCT05512390: A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Recruiting
1
154
Canada, US, RoW
ABBV-319
AbbVie
Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma
02/27
02/27
NV102 / NanoValent Pharma
No trials found

Download Options